Clicky

Takeda Pharmaceutical Company Limited(TAK)

Description: Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers medicines in various therapeutic areas, including gastroenterology; cancer; neurological and psychiatric diseases; and rare diseases, such as immunology and hematology, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Pharmaceutical Products Pharmacy Immunology Healthcare Products Rare Diseases Hematology Specialty Drugs Gastroenterology Takeda Pharmaceutical Company Nasdaq Biotechnology Index Cancer Center Arcturus Therapeutics University Of Texas Md Anderson Cancer Center Novimmune Multi Target Rare Disease Quasi Drug Consumer Products

Home Page: www.takeda.com

TAK Technical Analysis

1-1, Nihonbashi-Honcho 2-chome
Tokyo, 103-8668
Japan
Phone: 81 3 3278 2111


Officers

Name Title
Mr. Christophe Weber Pres, CEO & Representative Director
Mr. Constantine Saroukos CFO & Representative Director
Dr. Andrew S. Plump Pres of R&D and Representative Director
Dr. Seigo Izumo Chair of Management Board
Mr. Haruhiko Hirate Member of Management Board
Salvatore Alesci Member of Management Board and Head of R&D Global Science & Biomedical Policy
Norimasa Takeda Chief Accounting Officer & Corp. Controller
Mr. Iwaaki Taniguchi Sr. VP of Corp. Fin. & Controlling Department
Mr. Gabriele Ricci Chief Data & Technology Officer
Mr. Christopher David O'Reilly Global Head of Investor Relations & Global Fin.

Exchange: NYSE

Country: US

Currency: US Dollar ($)

Forward PE: 9.7276
Trailing PE: 29.6154
Price-to-Book MRQ: 0.9814
Price-to-Sales TTM: 0.0126
IPO Date: 2008-10-27
Fiscal Year End: March
Full Time Employees: 47347
Back to stocks